Deciphera Pharmaceuticals company info

What does Deciphera Pharmaceuticals do?
Deciphera Pharmaceuticals (NASDAQ:DCPH) is a biopharmaceutical company focused on the discovery, development, and commercialization of important new medicines to improve the lives of people with cancer. The company's innovative approach is centered on a deep understanding of kinase biology and kinase inhibitors, a class of drugs known for their ability to block key enzyme targets involved in cancer and other diseases. Deciphera is engaged in advancing a diverse pipeline of drug candidates that aim to address unmet needs in the treatment of various cancers, with a keen focus on developing targeted therapies that tackle resistant and difficult-to-treat cancers. The main objective of Deciphera is to bring breakthrough treatments to patients by pushing the boundaries of science and pioneering new pathways to fight cancer.
Deciphera Pharmaceuticals  company media
Company Snapshot

How many people does Deciphera Pharmaceuticals employ?

people
Employees
300

What sector is Deciphera Pharmaceuticals in?

pie chart
Sector
Health Care

Where is the head office for Deciphera Pharmaceuticals ?

location pin
Head Office
Waltham, United States

What year was Deciphera Pharmaceuticals founded?

founded flag
Year Founded
2003
What does Deciphera Pharmaceuticals specialise in?
/Cancer Therapeutics /Drug Development /Targeted Oncology /Kinase Inhibitors /Medical Research /Clinical Trials

What are the products and/or services of Deciphera Pharmaceuticals ?

Overview of Deciphera Pharmaceuticals offerings
QINLOCK (ripretinib), a kinase inhibitor approved for the treatment of advanced gastrointestinal stromal tumors (GIST) after prior therapy with 3 or more kinase inhibitors.
DCC-2618, an investigational drug targeting a broad spectrum of KIT and PDGFRA mutations in gastrointestinal stromal tumors, aimed at overcoming resistance to current treatments.
Rebastinib, in development as a combination therapy with chemotherapy for the treatment of solid tumors, focusing on inhibiting TIE2-mediated angiogenesis.
DCC-3014, targeting the CSF1R pathway, is being explored for potential use in various tumor types and tenosynovial giant cell tumor (TGCT), aiming at tumor microenvironment modulation.
Vimseltinib (DCC-3014) for the treatment of tenosynovial giant cell tumor, focusing on inhibiting the CSF-1R pathway, aiming to reduce tumor size and alleviate symptoms.
An extensive pipeline focusing on kinase inhibitor technologies intended for the development of treatments across a broad range of cancers.

Who is in the executive team of Deciphera Pharmaceuticals ?

Deciphera Pharmaceuticals leadership team
  • Mr. Steven L. Hoerter
    Mr. Steven L. Hoerter
    President, CEO & Director
  • Mr. Thomas Patrick Kelly J.D.
    Mr. Thomas Patrick Kelly J.D.
    Executive VP, CFO & Treasurer
  • Mr. Daniel C. Martin
    Mr. Daniel C. Martin
    Senior VP & Chief Commercial Officer
  • Dr. Matthew L. Sherman M.D.
    Dr. Matthew L. Sherman M.D.
    Executive VP & Chief Medical Officer
  • Dr. Kevin  Brodbeck Ph.D.
    Dr. Kevin Brodbeck Ph.D.
    Senior VP & Chief Technical Officer
  • Dr. Dashyant  Dhanak Ph.D.
    Dr. Dashyant Dhanak Ph.D.
    Executive VP & Chief Scientific Officer
  • Jennifer  Larson
    Jennifer Larson
    Senior Vice President of Finance & Investor Relations
  • Mr. Jeffrey M. Held J.D.
    Mr. Jeffrey M. Held J.D.
    Senior VP & General Counsel